Latest Breaking News On - B drug pricing program - Page 4 : comparemela.com

An appeals court has upheld a lower court ruling on 340B that sided with drug manufacturers. At issue is whether pharmaceutical companies can limit distribution of discounted drugs in the 340B program. The U.S. Court of Appeals for the District of Columbia has said that they can. The May 21 ruling issued by Circuit Court Judge Gregory Katsas found for Novartis Pharmaceuticals

District of columbiaUnited statesKinga krzeminska gettyGregory katsasMaureen testoniBeth feldpushB healthDepartment of healthUs department of healthCircuit courtUnited therapeutics corporationPublic health serviceB drug pricing programNovartis pharmaceuticals corporationGovernment accountability officeUs court